Payment overview · 2025
General Payments
$115,880.56
281 reported records · 18 companies
Healthcare provider profile · identity verified
John Gorham Winscott, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · JACKSON, MS · NPI 1124113667
Verified facts
What the public records show
CMS Open Payments records show John Gorham Winscott, M.D. received $115,880.56 in general payments during 2025 across 281 reported records.
Medtronic, Inc. accounted for 59.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$68,512.33 | 59.1% | 187 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $44,595.34 | 38.5% | 56 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $1,148.71 | 1.0% | 5 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $436.50 | 0.4% | 8 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $318.51 | 0.3% | 4 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $154.85 | 0.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.21 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.14 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.91 | 0.1% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $90.55 | 0.1% | 5 | 2025 |
| Innovation Technologies Inc | Unresolved — no canonical attribution shown | $64.18 | 0.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $58.91 | 0.1% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $57.42 | 0.1% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $44.53 | 0.0% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $30.29 | 0.0% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $29.23 | 0.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $17.52 | 0.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.43 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,025.00 | 7 |
| Consulting Fee | $41,625.00 | 22 |
| Travel and Lodging | $17,740.60 | 49 |
| Food and Beverage | $9,489.96 | 203 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $52,843.87 | 53 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $44,595.34 | 56 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $9,407.70 | 57 | 2025 |
Source payment records
|
|||||
| MO.MA ULTRA Normalized: mo ma ultra |
Device | Medtronic, Inc. | $1,221.82 | 11 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $1,148.71 | 5 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $1,148.71 | 5 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $737.32 | 35 | 2025 |
Source payment records
|
|||||
| SPIDERFX Normalized: spiderfx |
Device | Medtronic, Inc. | $537.73 | 12 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $249.24 | 6 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $238.61 | 2 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $219.80 | 3 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $184.70 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $154.85 | 3 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $128.26 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.21 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $107.23 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $98.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $93.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.91 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $90.55 | 5 | 2025 |
Source payment records
|
|||||
| IRRISEPT Normalized: irrisept |
Device | Innovation Technologies Inc | $64.18 | 2 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $44.53 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $40.87 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 173 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 130 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 31 |
| Carvedilol | Carvedilol | 69 | 28 |
| Losartan Potassium | Losartan Potassium | 59 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 18 |
| Furosemide | Furosemide | 47 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 44 | 17 |
| Lisinopril | Lisinopril | 43 | 17 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Eliquis | Apixaban | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 14 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Spironolactone | Spironolactone | 26 | 11 |
| Nitroglycerin | Nitroglycerin | 25 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Gabapentin | Gabapentin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115,880.56 · 281 records | Medtronic, Inc. | ABRE, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, Asahi Coronary Wires, Asahi Peripheral Vascular Wires, Assure WCD, CARDIVA VASCADE 6/7F VCS, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, Coronary Other, ENDOCROSS Device, ENROUTE Transcarotid Neuroprotection System, FARXIGA, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, HAWKONE, IN.PACT ADMIRAL, IN.PACT AV, IRRISEPT, Indigo System, JARDIANCE, LEQVIO, MO.MA ULTRA, SPIDERFX, SYMPHONY CATHETER, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TURBOHAWK, Torus Stent Graft System, VENASEAL, WATCHMAN Access System, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error